SCHEMBL11973616

SCHEMBL11973616

Nc1ccccc1S(=O)(=O)Nc1cccc2nccnc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 15/20 0.71
▸ MEN1 O00255 5/20 0.71
▸ KMT2A Q03164 5/20 0.71
▸ TDP1 Q9NUW8 5/20 0.71
▸ NFKBIA P25963 4/20 0.71
▸ RELA Q04206 3/20 0.71
▸ KDM4E B2RXH2 1/20 0.49
▸ USP2 O75604 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ GAA P10253 1/20 0.47
▸ MDM4 O15151 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ G6PD P11413 1/20 0.45
▸ AGTR1 P30556 1/20 0.45
▸ METAP2 P50579 1/20 0.45
▸ METAP1 P53582 1/20 0.45
▸ GLO1 Q04760 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL460773 0.83 SLC40A1 (1.00) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL31676665 0.83 SLC40A1 (1.00) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL3269491 0.80 SLC40A1 (0.68) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL11973610 0.79 NFKBIA (0.74) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL11973816 0.79 SLC40A1 (0.65) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL11972882 0.79 SLC40A1 (0.71) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL12659884 0.78 POLB (0.66) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL14360674 0.77 GLO1 (0.72) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL1891388 0.76 L3MBTL1 (0.54) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL11973857 0.76 SLC40A1 (0.61) SLC40A1MEN1KMT2ATDP1NFKBIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 — — EP disclosed
WO-2012110603-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — WO disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885MEN1 2680/4885KMT2A 3298/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885MEN1 2680/4885KMT2A 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback